Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Andrew Kalin

Pain Medicine Goshen, IN Medical Doctor

NPI 1811100043 CMS profile 414720

1824 Dorchester Ct Ste A, Goshen, IN 46526

Open in the dashboard

General payments

$11,839

175 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Andrew Kalin of Goshen, IN is reported in the CMS Open Payments database as having received $11,839 across 175 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 84th percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $640 11
2024 General $655 8
2023 General $4,844 30
2022 General $298 7
2021 General $631 11
2020 General $1,981 29
2019 General $2,791 79

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Andrew Kalin
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to Andrew Kalin were reported at $640. Among 2,779 Pain Medicine profiles paid that year, the median was $458 and the middle half received between $124 and $1,401.

Show as a table
Year Andrew Kalin Pain Medicine median Middle half National median
2019 $2,791 $498 $126–$1,682 $163
2020 $1,981 $284 $80–$910 $114
2021 $631 $399 $112–$1,219 $132
2022 $298 $455 $137–$1,484 $149
2023 $4,844 $484 $128–$1,495 $160
2024 $655 $498 $131–$1,540 $164
2025 $640 $458 $124–$1,401 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Saluda Medical Americas, Inc. $4,571 29 payments
  2. Abbott Laboratories $2,726 34 payments
  3. Boston Scientific Corporation $1,482 18 payments
  4. Nevro Corp. $957 23 payments
  5. Stryker Corporation $316 7 payments
  6. BIOTRONIK NRO, Inc. $289 3 payments
  7. Medtronic, Inc. $232 6 payments
  8. Collegium Pharmaceutical, Inc. $216 15 payments
  9. MML US, Inc. $169 1 payment
  10. SPR Therapeutics, Inc $141 1 payment
  11. Other $740 38 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,749 158 payments
  2. Travel and Lodging $4,090 17 payments
Products named General payments · program years 2019–2025
  1. Evoke SCS $4,042 20 payments
  2. Neuromodulation Dspsbls and Accs $1,267 12 payments
  3. SPECTRA WAVEWRITER $1,041 11 payments
  4. Proclaim Family of SCS IPGs $936 15 payments
  5. Evoke $529 9 payments
  6. Omnia $495 9 payments
  7. Senza Spinal Cord Stimulation System $462 14 payments
  8. Prospera $289 3 payments
  9. MILD DEVICE KIT $210 3 payments
  10. XTAMPZA $201 13 payments
  11. Other $2,625 90 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

387

Median for Interventional Pain Management: 1,220

Drug cost

$6,928

Median for Interventional Pain Management: $39,344

Branded share of claims

50.4%

Median for Interventional Pain Management: 34.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 152 $3,596
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 28 $1,267
Gabapentin Generic 75 $1,003
Pregabalin Generic 82 $658
Acetaminophen-Codeine Acetaminophen With Codeine Brand 15 $254
Tramadol Hcl Generic 35 $151

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,476 Part D prescribers listed as Interventional Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 43 billing codes

Paid by Medicare

$153,728

Of which drugs: $418

Medicare patients

280

Average age 75

Services billed

2,640

157 women, 123 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 36%
Ischemic heart disease 31%
Chronic kidney disease 28%
Depression 21%
COPD 20%
Atrial fibrillation 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 73 392 $279
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 87 1,140 $97
Infusion, normal saline solution, sterile (500 ml = 1 unit) J7040 Office 11 14 $14
Injection, fentanyl citrate, 0.1 mg J3010 Office 11 14 $10
Injection, midazolam hydrochloride, per 1 mg J2250 Office 11 26 $3

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

175 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record